{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:37:36Z","timestamp":1777693056584,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T00:00:00Z","timestamp":1457913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Seventh Framework Program from the European Union","award":["202059"],"award-info":[{"award-number":["202059"]}]},{"name":"Agiko Stipend of the Netherlands Organisation of Health Research and Development","award":["92003573"],"award-info":[{"award-number":["92003573"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The definition of hereditary prostate cancer (HPC) is based on family history and age at onset. Intuitively, HPC is a serious subtype of prostate cancer but there are only limited data on the clinical phenotype of HPC. Here, we aimed to compare the prognosis of HPC to the sporadic form of prostate cancer (SPC).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>HPC patients were identified through a national registry of HPC families in the Netherlands, selecting patients diagnosed from the year 2000 onward (n\u2009=\u2009324). SPC patients were identified from the Netherlands Cancer Registry (NCR) between 2003 and 2006 for a population\u2010based study into the genetic susceptibility of PC (n\u2009=\u20091,664). Detailed clinical data were collected by NCR\u2010registrars, using a standardized registration form. Follow\u2010up extended up to the end of 2013. Differences between the groups were evaluated by cross\u2010tabulations and tested for statistical significance while accounting for familial dependency of observations by GEE. Differences in progression\u2010free and overall survival were evaluated using \u03c7<jats:sup>2<\/jats:sup> testing with GEE in a proportional\u2010hazards model.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>HPC patients were on average 3 years younger at diagnosis, had lower PSA values, lower Gleason scores, and more often locally confined disease. Of the HPC patients, 35% had high\u2010risk disease (NICE\u2010criteria) versus 51% of the SPC patients. HPC patients were less often treated with active surveillance. Kaplan\u2013Meier 5\u2010year progression\u2010free survival after radical prostatectomy was comparable for HPC (78%) and SPC (74%; <jats:italic>P<\/jats:italic>\u2009=\u20090.30). The 5\u2010year overall survival was 85% (95%CI 81\u201389%) for HPC versus 80% (95%CI 78\u201382%) for SPC (<jats:italic>P<\/jats:italic>\u2009=\u20090.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>HPC has a favorable clinical phenotype but patients more often underwent radical treatment. The major limitation of HPC is the absence of a genetics\u2010based definition of HPC, which may lead to over\u2010diagnosis of PC in men with a family history of prostate cancer. The HPC definition should, therefore, be re\u2010evaluated, aiming at a reduction of over\u2010diagnosis and overtreatment among men with multiple relatives diagnosed with PC. <jats:italic>Prostate 76:897\u2013904, 2016<\/jats:italic>. \u00a9 2016 The Authors. <jats:italic>The Prostate<\/jats:italic> published by Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.23179","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T11:52:00Z","timestamp":1458301920000},"page":"897-904","source":"Crossref","is-referenced-by-count":10,"title":["The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited"],"prefix":"10.1002","volume":"76","author":[{"given":"Ruben G.","family":"Cremers","sequence":"first","affiliation":[{"name":"Radboud University Medical Center Radboud Institute for Health Sciences Nijmegen The Netherlands"},{"name":"The Netherlands Foundation for the Detection of Hereditary Tumours Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja K.","family":"Aben","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Radboud Institute for Health Sciences Nijmegen The Netherlands"},{"name":"Netherlands Comprehensive Cancer Organisation Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Radboud Institute for Health Sciences Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P. Michiel","family":"Sedelaar","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Radboud Institute for Health Sciences Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans F.","family":"Vasen","sequence":"additional","affiliation":[{"name":"The Netherlands Foundation for the Detection of Hereditary Tumours Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita H.","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Radboud Institute for Health Sciences Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambertus A.","family":"Kiemeney","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Radboud Institute for Health Sciences Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710083171501"},{"key":"e_1_2_7_4_1","unstructured":"Stichting Opsporing Erfelijke Tumoren en de Vereniging Klinische Genetica Nederland Werkgroep Klinische Oncogenetica. Erfelijke tumoren: Richtlijnen voor diagnostiek en preventie: Stichting Opsporing Erfelijke Tumoren en de Vereniging Klinische Genetica Nederland Werkgroep Klinische Oncogenetica;2010."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60525-0"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35617-3"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.02.002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-013-1384-2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22933"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23165"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29949"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1998.00801.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64997-X"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.448"},{"key":"e_1_2_7_15_1","unstructured":"National Institute for Health and Care Excellence. CG175: Prostate cancer: Diagnosis and treatment. NICE Clinical Guidelines. London: National Institute for Health and Care Excellence;2014."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10657"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20568"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2560"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22933"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3094"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2741\/2374"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23179","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23179","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23179","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.23179","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:50:55Z","timestamp":1696499455000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1002\/pros.23179"],"URL":"https:\/\/doi.org\/10.1002\/pros.23179","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,14]]}}}